Validation of a commercially available indirect assay for SARS-CoV-2 neutralising antibodies using a pseudotyped virus assay.
Validation of a commercially available indirect assay for SARS-CoV-2 neutralising antibodies using a pseudotyped virus assay.
复制标题
DOI：
10.1016/j.jinf.2021.03.010
复制
发表时间：
2021-05
期刊：
影响因子：
--
通讯作者：
Reeves MB
中科院分区：
文献类型：
--
作者：
Murray MJ;McIntosh M;Atkinson C;Mahungu T;Wright E;Chatterton W;Gandy M;Reeves MB
基于ELISA的cPass检测提供了Spike RBD结合抗体的测量方法。在cPass ELISA上的结合与假型病毒中和密切相关。基于elisa的替代检测提供了中和能力的快速数据。为了评估市售CE-IVD，基于elisa的替代中和试验（cPass, Genscript）是否提供了人类血清对SARS-CoV-2中和的真实测量，并进一步确定测量对S RBD的反应是否可作为对整个S蛋白反应的诊断有用的替代方法。对30例患者的血清样本进行抗np反应测定，通过替代中和试验进行“中和”，并利用两种靶细胞系进行sars - cov - 2s假型病毒试验进行中和。使用线性回归测量测定法之间的相关性。在替代中和试验中观察到的反应与在两种假型病毒试验中观察到的反应表现出极强的、高度显著的正相关。经测试的基于elisa的替代测定以更快和高度自动化的方式提供了功能性免疫反应的免疫学有用测量。它还强调，检测抗rbd中和抗体本身是一种有效的措施，以消除病毒感染的能力。
An ELISA based cPass assay provides a measure of Spike RBD binding antibodies. Binding in a cPass ELISA correlates strongly with pseudotyped virus neutralisation. ELISA-based surrogate assays provide rapid data on neutralising capacity. To assess whether a commercially available CE-IVD, ELISA-based surrogate neutralisation assay (cPass, Genscript) provides a genuine measure of SARS-CoV-2 neutralisation by human sera, and further to establish whether measuring responses against the RBD of S was a diagnostically useful proxy for responses against the whole S protein. Serum samples from 30 patients were assayed for anti-NP responses, for ‘neutralisation’ by the surrogate neutralisation assay and for neutralisation by SARS-CoV-2 S pseudotyped virus assays utilising two target cell lines. Correlation between assays was measured using linear regression. The responses observed within the surrogate neutralisation assay demonstrated an extremely strong, highly significant positive correlation with those observed in both pseudotyped virus assays. The tested ELISA-based surrogate assay provides an immunologically useful measure of functional immune responses in a much quicker and highly automatable fashion. It also reinforces that detection of anti-RBD neutralising antibodies alone is a powerful measure of the capacity to neutralise viral infection.
登录
查看更多内容
影响因子：
64.8
作者：
Gaebler C;Wang Z;Lorenzi JCC;Muecksch F;Finkin S;Tokuyama M;Cho A;Jankovic M;Schaefer-Babajew D;Oliveira TY;Cipolla M;Viant C;Barnes CO;Bram Y;Breton G;Hägglöf T;Mendoza P;Hurley A;Turroja M;Gordon K;Millard KG;Ramos V;Schmidt F;Weisblum Y;Jha D;Tankelevich M;Martinez-Delgado G;Yee J;Patel R;Dizon J;Unson-O'Brien C;Shimeliovich I;Robbiani DF;Zhao Z;Gazumyan A;Schwartz RE;Hatziioannou T;Bjorkman PJ;Mehandru S;Bieniasz PD;Caskey M;Nussenzweig MC
通讯作者：
Nussenzweig MC
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
影响因子：
64.8
作者：
Hoffmann, Markus;Moesbauer, Kirstin;Poehlmann, Stefan
通讯作者：
Poehlmann, Stefan
影响因子：
15.3
作者：
Schmidt, Fabian;Weisblum, Yiska;Bieniasz, Paul D.
通讯作者：
Bieniasz, Paul D.
影响因子：
30.3
作者：
Case, James Brett;Rothlauf, Paul W.;Whelan, Sean P. J.
通讯作者：
Whelan, Sean P. J.